# Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

> **NCT06195670** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 220 (estimated)

## Conditions studied

- CRC
- Metastatic Colorectal Cancer
- Metastatic Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Experimental
- **DRUG:** Active Comparator

## Key facts

- **NCT ID:** NCT06195670
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01
- **Primary completion:** 2026-01
- **Final completion:** 2027-01
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2024-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06195670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06195670, "Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06195670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*